This is a working overview of AOD9604, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-12 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
== History == Chemical equilibria in marine and freshwater systems were calculated according to various conventions for most of the 20th century, which led to discrepancies among laboratories' calculations and limited scientific reproducibility. CO2SYS was first published by Ernie Lewis and Doug Wallace in 1998 as a DOS-interface program written in QBasic. Subsequent developments have included several MATLAB implementations, two Microsoft Excel templates, a Python package "PyCO2SYS", and an R package inspired by CO2SYS, "seacarb". Development of the various CO2SYS programs continues as of 2021 with the addition of more chemical equilibrium parameters and compatibility with a wider range of environments, e.g. anoxic waters.
=== Enhancing hydrophobic interaction === Okano’s group expanded on their success by using different modifiers to enhance hydrophobicity through the attachment of butyl methacrylate (BMA), a hydrophobic comonomer. For simplification the resultant polymer has been labeled as IBc (isopropylacrylamide butyl methacrylate copolymer). The polymers were synthesized using radical telomerization with varying BMA content. Where pure PNIPAAm was unable to resolve hydrophobic steroids at any temperature, IBc-grafted silica stationary phases were able to resolve steroid peaks with increasingly retarded retention times in correlation to both increased BMA content and increased temperature. They went on to develop a method to separate phenylthiohydantoin(PTH)-amino acids using their IBc stationary phase with a stronger emphasis of implementing environmentally friendly conditions using a purely aqueous phase in HPLC. Another group separated catechins using PNIPAAm.
== L == Lac repressor – lactic acid autotroph – lagging strand – lambda phage – larva – leading strand – leaf – White blood cells – lichen – life form – life – light reactions – limbic system – limnology – Lineweaver-Burk diagram – lipase – lipid – liver – locus – long-term potentiation – Louis Pasteur – lung – Lynn Margulis – Lyon hypothesis – lysis – lysozyme – lytic cycle
== Martin and Synge and partition chromatography == Chromatography methods changed little after Tsvet's work until the explosion of mid-20th-century research in new techniques, particularly thanks to the work of Archer John Porter Martin and Richard Laurence Millington Synge. By "the marrying of two techniques, that of chromatography and that of countercurrent solvent extraction", Martin and Synge developed partition chromatography to separate chemicals with only slight differences in partition coefficients between two liquid solvents. Martin, who had previously been working in vitamin chemistry (including attempts to purify vitamin E), began collaborating with Synge in 1938, brought his experience with equipment design to Synge's project of separating amino acids. After unsuccessful experiments with complex countercurrent extraction machines and liquid-liquid chromatography methods where the liquids move in opposite directions, Martin hit on the idea of using silica gel in columns to hold water stationary while an organic solvent flows through the column. Martin and Synge demonstrated the potential of the methods by separating amino acids marked in the column by the addition of methyl red. In a series of publications beginning in 1941, they described increasingly powerful methods of separating amino acids and other organic chemicals. In pursuit of better and easier methods of identifying the amino acid constituents of peptides, Martin and Synge also turned to other chromatography media.
Sources: en.wikipedia.org
{\displaystyle {\begin{array}{lll}M({\ce {He}})&=4.002602(2)\times M_{\mathrm {u} }&=4.002602(2){\text{ g/mol}}\\M({\ce {Ne}})&=20.1797(6)\times M_{\mathrm {u} }&=20.1797(6){\text{ g/mol}}\\M({\ce {Fe}})&=55.845(2)\times M_{\mathrm {u} }&=55.845(2){\text{ g/mol}}\\M({\ce {Cu}})&=63.546(3)\times M_{\mathrm {u} }&=63.546(3){\text{ g/mol}}\\M({\ce {Ag}})&=107.8682(2)\times M_{\mathrm {u} }&=107.8682(2){\text{ g/mol}}\end{array}}}
=== James Ashford === James Ashford (Tom Stourton) is the CEO of Ashford Asset Management, and one of Lumi's primary investors. The day of the company's IPO, he confronts Henry about Lumi's inflated quarterly earnings reports and asks whether Pierpoint overvalued the company; Henry dismisses Ashford's concerns and returns his shares, forcing Pierpoint to scramble to find new investors. Harper later runs into Ashford in the park and learns from him that most banks are backtracking on their ESG investments, corroborating what she overheard Sweetpea telling Yasmin about Pierpoint's impending debt crisis. Harper uses what Ashford told her as legal cover for shorting Pierpoint. In series 4, Ashford, who invested in Harper's short-only fund at Otto Mostyn's asset management firm, angrily confronts her about denying investors' redemption requests following her controversial short of porn aggregator Siren. He is revealed to have been in a sexual relationship with Harper, and tips her off that Otto is restricting her from jeopardizing his political connections in hopes of obtaining a peerage. Ashford suddenly collapses from a minor stroke and is removed from the office by paramedics.
Brew 39 was sold in Dublin from late 2005 until early 2006. It had the same alcohol content (ABV) as Guinness Draught, used the same gas mix and settled in the same way, but had a slightly different taste. Many found it to be lighter in taste, somewhat closer to Beamish stout than standard Irish Guinness. The Beamish & Crawford Brewery was established in 1792 in the City of Cork, and was bought by Guinness in 1833. Toucan Brew was introduced in May 2006. It was named after the cartoon toucan used in many Guinness advertisements. This beer had a crisper taste with a slightly sweet aftertaste due to its triple-hopped brewing process. North Star was introduced in October 2006 and sold into late 2007. Three million pints of North Star were sold in the latter half of 2007. Despite an announcement in June 2007 that the fourth Brewhouse stout would be launched in October that year, no new beer appeared and, at the end of 2007, the Brewhouse series appeared to have been quietly cancelled. From early 2006, Guinness marketed a "surger" unit in Britain. This surger device, marketed for use with cans consumed at home, was "said to activate the gases in the canned beer" by sending an "ultra-sonic pulse through the pint glass" sitting upon the device. Withdrawn Guinness variants include Guinness's Brite Lager, Guinness's Brite Ale, Guinness Light, Guinness XXX Extra Strong Stout, Guinness Cream Stout, Guinness Milk Stout, Guinness Irish Wheat, Guinness Gold, Guinness Pilsner, Guinness Breó (a slightly citrusy wheat beer), Guinness Shandy, and Guinness Special Light.
Gordon Freeman, PhD, is the silent protagonist of the Half-Life series and the playable character in Half-Life and all games in the Half-Life 2 series. He is a theoretical physicist and holds a PhD from MIT in that field. At the time of Half-Life, he works at Black Mesa Research Facility, a facility in New Mexico, conducting nuclear and subatomic research. After being at ground zero during the "resonance cascade", Gordon fights his way through Black Mesa and eventually reaches the Lambda Complex where a group of surviving scientists are getting ready to teleport him to Xen in order for Gordon to kill a large entity (The "Nihilanth") holding the portals open in Xen. In doing so he frees the alien race of vortigaunts from slavery and is hired by the G-Man for an unknown future job. In Half-Life 2 he is re-awoken from stasis by the G-man and meets up with the resistance on Earth against the Combine. The resistance view him as a very important figure due to the mythos surrounding what he did in Black Mesa. He eventually becomes one of the leading figures in the resistance, almost single-handedly destroying the Combine prison, Nova Prospekt, and signaling the uprising to begin. During the uprising, Gordon fights his way through the ruined streets of City 17 and enters the Citadel. He and Alyx Vance attempt to stop Dr. Wallace Breen from teleporting to a Combine Planet and blow up the teleporter he was trying to use.
== Structure == The obestatin structure to the right was determined by NMR. The length of the polypeptide was found to be 24 residues with a secondary structure 29% helical. Specifically 2 helices and 7 residues are formed.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.